Oncolytics Biotech Inc.
ONC.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -23.14M | -20.32M | -20.72M | -20.95M | -20.60M |
| Total Depreciation and Amortization | 297.00K | 318.40K | 318.20K | 318.10K | 298.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 560.80K | -2.99M | -3.11M | -2.64M | -2.10M |
| Change in Net Operating Assets | 2.61M | 4.42M | 3.99M | 2.44M | 1.31M |
| Cash from Operations | -19.67M | -18.57M | -19.52M | -20.84M | -21.09M |
| Capital Expenditure | -175.20K | -173.10K | -149.60K | -36.30K | -5.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 5.04M | 10.10M | 15.03M |
| Cash from Investing | -175.20K | -173.10K | 4.89M | 10.06M | 15.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -348.00K | -352.00K | -374.00K | -409.00K | -407.00K |
| Issuance of Common Stock | 7.74M | 4.13M | 27.65M | 29.40M | 33.28M |
| Repurchase of Common Stock | -- | -882.00K | -882.00K | -882.00K | -882.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -751.00K | 2.15M | 105.00K | 109.00K | 0.00 |
| Cash from Financing | 4.81M | 3.71M | 19.70M | 21.01M | 23.80M |
| Foreign Exchange rate Adjustments | 1.16M | 46.80K | 529.50K | 75.00K | -382.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.87M | -14.99M | 5.61M | 10.31M | 17.36M |